Compare CHMI & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | ADVB |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | 12 | 31 |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 109.2M |
| IPO Year | N/A | N/A |
| Metric | CHMI | ADVB |
|---|---|---|
| Price | $2.65 | $5.13 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 144.2K | ★ 200.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 15.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.73 | N/A |
| P/E Ratio | $139.30 | ★ $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $0.19 |
| 52 Week High | $3.67 | $5.82 |
| Indicator | CHMI | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 86.08 |
| Support Level | $2.50 | $0.41 |
| Resistance Level | $2.74 | $5.75 |
| Average True Range (ATR) | 0.07 | 0.65 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 50.18 | 80.54 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.